Support innovative projects in development and new production technologies, thus building skills for the future. With this objective, Johnson & Johnson Innovative Medicine announced its commitment to Italy yesterday: an investment of 580 million euros over the next five years, of which 125 million euros will support an increase of over 25% in the production capacity of the plant of Latin. An investment with which – as underlined by Mario Sturion, managing director of J&JIM Italia – the company, strongly rooted in Italy since 1975, “renews its trust” in our country and strengthens its “concrete commitment to promote and increase the attractiveness and the competitiveness of the country, increasing research and excellent pharmaceutical production”. The announcement is, in fact, part of a strategic plan which envisaged a growth in investments in Italy of 9.2% every year in the period 2019-2023, three times higher than the average of the pharmaceutical sector, according to a new studio of The European House – Ambrosetti. This has translated into a 15% increase in employment in Italy over the last five years, reaching approximately 1,400 employees across the country.
Johnson & Johnson’s focus on Research & Development remains strong. In the last five years the company has invested almost 50 million euros in Italy (+11.7% every year since 2019). In 2023, J&JIM’s attention on the R&D front has translated into the management of 114 clinical studies and collaboration with 993 research centers in Italy, offering access to treatment to more than 5 thousand patients. The investment of 580 million euros “marks Italian leadership in pharmaceuticals in Europe” commented the Minister of Business and Made In Italy, Adolfo Urso, underlining how large companies are a driving force for SMEs. “The pharmaceutical sector – explained Urso – is the most striking example of how large companies and SMEs can grow together. The pharmaceutical sector has become a new growth model for Made in Italy, thanks to the impressive investments in research and innovation. This growth, 60% driven by large foreign multinationals, allows the local production fabric involved in the supply chain – made up of large Italian companies and a network of thousands of innovative small and medium-sized enterprises that cooperate and export to global markets – to grow equally and promotes its internationalization. To make our country attractive for foreign companies, we have reformed our legislative system to create an authorization ‘fast track’ for those who invest in Italy”.
The Latina site, an important asset in J&J’s global supply chain, produces more than four billion tablets per year, for approximately 30 different products, and 97% of production is exported, reaching patients around the world. The investment plan will allow an increase in production capacity by over 25% thanks to initiatives aimed at supporting products under development and new production technologies. New projects include the Flex Line, to more efficiently manage the packaging of small production batches, and a new continuous production line that will reduce total end-to-end production time and allow medicines to reach patients more quickly. quickly.
